Payment overview · 2025
General Payments
$243.66
13 reported records · 12 companies
Healthcare provider profile · identity verified
Kathy Geraets, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX FALLS, SD · NPI 1225472152
Verified facts
What the public records show
CMS Open Payments records show Kathy Geraets, MD received $243.66 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.77 | 16.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.20 | 9.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.22 | 9.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.37 | 8.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.31 | 7.9% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $19.12 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.80 | 7.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.75 | 6.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.30 | 6.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.27 | 6.7% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.00 | 6.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.55 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.66 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 408 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 53 |
| Omeprazole | Omeprazole | 234 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 42 |
| Lisinopril | Lisinopril | 195 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 48 |
| Losartan Potassium | Losartan Potassium | 174 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 39 |
| Sertraline Hcl | Sertraline Hcl | 114 | 26 |
| Alendronate Sodium | Alendronate Sodium | 113 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 23 |
| Metformin Hcl | Metformin Hcl | 80 | 16 |
| Warfarin Sodium | Warfarin Sodium | 77 | 14 |
| Gabapentin | Gabapentin | 75 | 18 |
| Meloxicam | Meloxicam | 73 | 21 |
| Metformin Hcl Er | Metformin Hcl | 72 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 15 |
| Furosemide | Furosemide | 69 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 15 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 18 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 22 |
| Tramadol Hcl | Tramadol Hcl | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 14 |
| Potassium Chloride | Potassium Chloride | 45 | 13 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Eliquis | Apixaban | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.66 · 13 records | Amgen Inc. | Azstarys, EVENITY, GVOKE HYPOPEN, INSPIRE, JARDIANCE, JOURNAVX, MOUNJARO, NEFFY, NURTEC ODT, QULIPTA, Qelbree, TZIELD, UBRELVY, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error